Zimanyi I A, Fathi Z, Poindexter G S
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7660, USA.
Curr Pharm Des. 1998 Aug;4(4):349-66.
Obesity is a serious health problem in the Western societies, therefore its treatment has become the subject of intense interest in the scientific community. A significant number of recent publications enlist different central and peripheral factors which play important roles in the regulation of food intake, body weight and energy expenditure. Neuropeptide Y, a 36 amino acid peptide, which is quite abundant in the brain, seems to be one of the more important players in these regulations. Recently five NPY receptors have been cloned and pharmacological evidence strongly supports the existence of a sixth receptor. There are many contradictory findings regarding which NPY receptor mediates the effect of NPY on food intake. This article will review the effects of NPY on the regulation of food intake and energy expenditure and will discuss the pharmacological and molecular evidence as to which NPY receptor(s) mediate this effect. The review will also summarize the progress which has been made in the design of novel NPY-ergic ligands, especially NPY receptor antagonists, for potential use in the treatment of obesity.
肥胖在西方社会是一个严重的健康问题,因此其治疗已成为科学界密切关注的课题。最近大量的出版物列举了不同的中枢和外周因素,这些因素在食物摄入、体重和能量消耗的调节中起着重要作用。神经肽Y是一种由36个氨基酸组成的肽,在大脑中含量相当丰富,似乎是这些调节过程中较为重要的因素之一。最近已克隆出五种神经肽Y受体,药理学证据有力地支持了第六种受体的存在。关于哪种神经肽Y受体介导神经肽Y对食物摄入的影响,存在许多相互矛盾的研究结果。本文将综述神经肽Y对食物摄入和能量消耗调节的影响,并讨论关于哪种神经肽Y受体介导这种作用的药理学和分子证据。本综述还将总结在设计新型神经肽Y能配体,特别是神经肽Y受体拮抗剂方面所取得的进展,这些配体有望用于肥胖症的治疗。